Channels

22:58 EST 18th December 2014 | BioPortfolio

BioPortfolio's Channels offers visitors a single point of access to life science and healthcare subjects, technologies, products and services. For example ImmTAC developed by Immunocore, PolyXen developed by Xenetic Biosciences. Each dedicated Channel web page provides highly specific information sourced from BioPortfolio's unique collection of databases - news stories, corporate directory, clinical trials, medical and scientific information.

Organizations can request specific channel pages to be created to promote their products, technologies, research tools and services. BioPortfolio makes a nominal charge of between $40 to $50 per web page published. Each bespoke Channel page is managed by the registered member who can edit and amend over the 12 month subscription period. To start publishing content on BioPortfolio's Channels open http://www.bioportfolio.net/report/23346-biochannel-publish-content-on-products-technologies.html

Interested? Contact priority@bioportfolio.com

Showing Channels 1–25 of 4,200+

Monday 21st July 2014

Phoenix MarCom

Phoenix MarCom is a specialist marketing communications company, working with clients in the clean tech (including renewables, environmental technology, low carbon and sustainability), scientific and industrial market sectors. Phoenix offers a wide ran...

Tuesday 19th November 2013

Nuclear Medicine

Nuclear medicine is a medical specialty involving the application of radioactive substances in the diagnosis and treatment of disease. In nuclear medicine procedures, radionuclides are combined with other elements to form chemical compounds, or else c...

Wednesday 26th June 2013

Orphan Indications

Examples of Ophan Drug Indications include: Anaemia, sickle cell Cystic fibrosis (CF) Duchenne muscular dystrophy Glioma Graft vs host disease (GvHD) Hepatoma, liver cancer Hodgkin Lymphoma Leukaemia, acute lymphocytic (ALL) Leukaemia, acute my...

Orphan Drugs

An orphan drug is a pharmaceutical product aimed at rare diseases or disorders. The development of orphan drugs has been financially incentivised through US law via the ‘Orphan Drug Act of 1983’. The National Organization for Rare D...

Oncogenic BRAF in cancer

Oncogenic BRAF can result from mutations in the BRAF gene, which may cause the protein to become overactive. The most common alteration in the BRAF gene leads to the BRAFV600E mutation. Mutations in the BRAF gene allow for BRAF to signal independently of...

G-protein-coupled receptors (GPCRs)

GPCRs are a large family of cell surface receptors that respond to a variety of external signals. Binding of a signaling molecule to a GPCR results in G protein activation, which in turn triggers the production of any number of second messengers. Through...

Tuesday 4th June 2013

Vantictumab

Anti-Fzd7 (vantictumab, OMP-18R5) Vantictumab is OncoMed’s lead program in the Wnt pathway. Screened against the Frizzled 7 receptor, the antibody binds a conserved epitope on five of the Frizzled receptors. It has been shown in preclinical studi...

AUT00063

AUT00063 develpoed by Autifony Therapeutics, is a novel, orally active small molecule designed to selectively modulate Kv3 potassium channels, which are important in central auditory processing. Preclinical studies have shown that AUT00063 has the potent...

Friday 31st May 2013

Veregen

Veregen® is an ointment used to treat external genital warts. In the USA, Germany, Austria, Spain, Switzerland and Serbia, Veregen® is already marketed by our partners. Sales and marketing partnerships are also in place for this drug in a large n...

Eligard

Eligard® is a hormone compound for the treatment of advanced, hormone-dependent prostate cancer. The active ingredient (leuprolide acetate) significantly reduces the level of the male sex hormone testosterone, thus suppressing testosterone-dependent ...

Wednesday 29th May 2013

KIACTA

KIACTA™ (also known as eprodisate) is an orally bioavailable small molecule intended for the treatment of AA amyloidosis, an orphan indication that results from long-standing inflammatory conditions. KIACTA™ is partenered with global privat...

Tuesday 28th May 2013

SureSeq Solid Tumour Panel Sequencing Service

The SureSeq Solid Tumour Panel Sequencing Service utilises an enrichment panel comprising the full coding regions of 58 prioritised cancer genes. The aim of the panel is to improve cancer care by providing individualised patient profiles facilitating the...

Wednesday 22nd May 2013

Early Embryo Viability Assessment Test (Eeva)

Auxogyn’s non-invasive Early Embryo Viability Assessment Test (Eeva) may improve in vitro fertilization (IVF) outcomes by providing IVF clinics and patients with objective information on embryo viability. Eeva’s proprietary software automatic...

Tuesday 21st May 2013

Paroxysmal supraventricular tachycardia (PSVT)

Paroxysmal supraventricular tachycardia (PSVT) is episodes of rapid heart rate that start in a part of the heart above the ventricles. "Paroxysmal" means from time to time. The heart will suddenly start racing, then stop or slow down abruptly...

Xofigo (radium-223 dichloride)

New treatment for castration-resistant prostate cancer (CRPC) patients with bone metastases. Xofigo shown in a pivotal phase III trial to significantly improve overall survival. Xofigo® with the active ingredient radium 223 dichloride (radium 223...

Friday 17th May 2013

IFNα-Kinoid

Lupus : A major unmet medical need Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and tissue damage. It may affect multiple organ systems, incl...

TNF-Kinoid

Therapies targeting TNF have already demonstrated efficacy across a wide range of inflammatory diseases, including rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondulitis, psoriasis and Crohn’s disease. The target market for Kin...

Thursday 16th May 2013

Obinutuzumab

A glycoengineered, fully humanized IgG1 monoclonal antibody with potential antineoplastic activity. Obinutuzumab, a third generation type II anti-CD20 antibody, selectivity binds to the extracellular domain of the human CD20 antigen on malignant human B ...

UroGenRA - Genitourinary cancer array

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It was designed to detect gains and losses that frequently...

UGenRA - Genitourinary cancer array

UGenRA is a CGI custom-designed oligonucleotide array designed to detect gains and losses of genomic material in endometrial, ovarian, and cervical cancers. Endometrial hyperplasia is a precursor lesion of endometriod endometrial carcinoma (EEC) and sinc...

MatBA - Mature B-cell neoplasm array

Mature B-cell neoplasms arise in B-cells that have entered germinal centers within lymph nodes as part of the immune response. They display great heterogeneity at the clinical, pathologic, and genetic levels and represent 6-7% and 5-6% of all new estimat...

DNA-FISH Probes

Fluorescent in situ hybridization (FISH) is a sensitive and accurate technique that allows the detection of chromosome aberrations. In this method, a single-stranded fluorescent-labeled nucleic acid sequence (probe) complementary to a target genomic sequ...

Wednesday 15th May 2013

Coronavirus

Coronavirus were first identified in the 1960s, and were named after the crown-like projections on the surface of the virus. They cause respiratory infections in both humans and animals. Coronaviruses are a large family of viruses that includes viruses...

H7N9 Bird Flu Virus

Avian influenza A H7 viruses are a group of influenza viruses that normally circulate among birds. The avian influenza A(H7N9) virus is one subgroup among the larger group of H7 viruses. Although some H7 viruses (H7N2, H7N3 and H7N7) have occasionally be...

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual disease monitoring has become common practice in many ha...


Search BioPortfolio:
Loading
Advertisement
Advertisement